SenesTech, Inc. - Common Stock (SNES)
1.9200
-0.3400 (-15.04%)
NASDAQ · Last Trade: Mar 14th, 6:47 PM EDT
Detailed Quote
| Previous Close | 2.260 |
|---|---|
| Open | 1.800 |
| Bid | 1.700 |
| Ask | 2.010 |
| Day's Range | 1.800 - 2.110 |
| 52 Week Range | 1.300 - 6.240 |
| Volume | 287,151 |
| Market Cap | 23.41M |
| PE Ratio (TTM) | -0.4103 |
| EPS (TTM) | -4.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 65,877 |
Chart
About SenesTech, Inc. - Common Stock (SNES)
Senestech Inc is a biotechnology company focused on the development of innovative solutions for pest control through its proprietary platform that employs the principles of biology and technology. The company's primary aim is to create environmentally friendly products that effectively manage pest populations while minimizing harmful impacts on non-target species and ecosystems. By utilizing a unique approach to target specific species, Senestech seeks to meet the growing demand for sustainable pest management solutions in various agricultural and residential markets. Read More
News & Press Releases

SenesTech (SNES) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 12, 2026
Via Benzinga · November 11, 2025
SenesTech Q3 2025: Record revenue & strong product growth, but stock fell after a revenue miss. EPS beat estimates, showing improved cost control.
Via Chartmill · November 10, 2025
Via Benzinga · August 8, 2025
Via Benzinga · July 1, 2025
Via Benzinga · April 24, 2025
A discussion about the $4B rodent control market and the company’s game-changing product Evolve – a revolutionary form of rodent birth control.
Via Talk Markets · April 16, 2025
SenesTech, an under-the-radar biotech company with a focus on solving the global pest population problem through, humane fertility control measures, seems attractively valued.
Via Talk Markets · April 1, 2025
Via Benzinga · March 14, 2025
With no direct competition in the fertility control space and growing demand for non-lethal rodent management, could SNES be the next big winner? Find out in this deep-dive conversation with CEO Joel Fruendt.
Via Talk Markets · March 13, 2025
Via Benzinga · March 13, 2025
Via Benzinga · March 12, 2025

SenesTech shares lower as they exercise outstanding warrants for 374,718 shares at reduced price, plans to use proceeds for corporate purposes.
Via Benzinga · March 10, 2025

SenesTech is a small company with an innovative way for rodent control using induced infertility. They have rapidly expanded with pilot programs in major US cities and also globally in New Zealand and Australia.
Via Talk Markets · March 5, 2025
SenesTech's Evolve products are recent, but take a novel approach to rodent plagues, painlessly reducing reproduction velocity and the product is already taking off with huge distribution deals in place and rapidly improving company financials.
Via Talk Markets · February 19, 2025

SenesTech, a disruptive biotech firm, is quietly making major strides in municipal adoption, international expansion, and retail penetration.
Via Talk Markets · February 14, 2025

SenesTech is disrupting rodent control with Evolve, a fertility-based solution gaining traction in NYC & Baltimore.
Via Talk Markets · February 13, 2025

